Braidwell LP Takes $9.14 Million Position in Adlai Nortye Ltd. Sponsored ADR $ANL

Braidwell LP acquired a new position in Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 795,214 shares of the company’s stock, valued at approximately $9,145,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SmartHarvest Portfolios LLC lifted its holdings in shares of Adlai Nortye by 8.5% during the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock worth $113,000 after purchasing an additional 1,279 shares during the period. Renaissance Technologies LLC acquired a new position in Adlai Nortye in the 1st quarter worth approximately $457,000. ADAR1 Capital Management LLC purchased a new position in Adlai Nortye during the 1st quarter worth approximately $816,000. Affinity Asset Advisors LLC purchased a new position in Adlai Nortye during the 1st quarter worth approximately $1,140,000. Finally, Boone Capital Management LLC acquired a new stake in Adlai Nortye during the 2nd quarter valued at approximately $2,971,000. Institutional investors and hedge funds own 35.21% of the company’s stock.

Insider Transactions at Adlai Nortye

In related news, CFO Xiaofeng Ye sold 5,667 shares of the business’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total value of $80,754.75. Following the completion of the sale, the chief financial officer owned 147,757 shares of the company’s stock, valued at approximately $2,105,537.25. The trade was a 3.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Wall Street Analyst Weigh In

Several research firms have recently commented on ANL. Oppenheimer assumed coverage on shares of Adlai Nortye in a report on Thursday, May 28th. They issued an “outperform” rating and a $32.00 price objective on the stock. JonesTrading began coverage on shares of Adlai Nortye in a report on Thursday, May 14th. They set a “buy” rating and a $22.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Adlai Nortye in a research report on Tuesday, July 14th. Wall Street Zen raised shares of Adlai Nortye from a “hold” rating to a “buy” rating in a report on Saturday, August 22nd. Finally, Cantor Fitzgerald initiated coverage on Adlai Nortye in a research report on Monday, June 22nd. They set an “overweight” rating on the stock. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.25.

Adlai Nortye Price Performance

Shares of ANL opened at $13.85 on Thursday. Adlai Nortye Ltd. Sponsored ADR has a 12 month low of $0.88 and a 12 month high of $17.25. The stock’s 50 day moving average is $12.36 and its two-hundred day moving average is $11.31. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.